Enclosed please find herewith Audited financial results for the quarter and year ended March 31, 2026
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences reported strong full-year results for FY2026. Revenue from operations grew 6.9% to Rs 25,518 million from Rs 23,869 million in FY2025. Profit after tax increased 16.2% to Rs 5,645 million from Rs 4,856 million. EBITDA margin expanded to approximately 31.6% from 29.5% in the prior year. The Board recommended a final dividend of Rs 5 per share (250% on face value of Rs 2). An exceptional item of Rs 256.57 million was recorded due to statutory impact of new labour codes (gratuity Rs 170 million and compensated absences Rs 86.55 million). Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion. Cash and cash equivalents declined sharply from Rs 711 million to Rs 20 million due to heavy capital expenditure of Rs 3,071 million.
The company delivered healthy profit growth with margin expansion, indicating operational efficiency gains. The heavy capex spending reduced cash reserves but supports future growth. The clean audit opinion and dividend payout are positive signals for shareholders.